Technical Analysis for CALT - Calliditas Therapeutics AB
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 40.00 | -0.40% | -0.16 |
Earnings due: Nov 11
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Shooting Star Candlestick | Bearish | 0.00% | |
| Lizard Bearish | Bearish Day Trade Setup | 0.00% | |
| Cup with Handle | Other | 0.00% | |
| Wide Range Bar | Range Expansion | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| New 52 Week High | Strength | 0.00% | |
| BB Squeeze Ended | Range Expansion | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% |
Get a Trading Sidekick!
- Earnings date: 11/11/2024
Calliditas Therapeutics AB Description
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Pharmacy Medication Pharmaceutical Products Kidney Disease Renal Disease Pharmaceutics
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 43.0 |
| 52 Week Low | 15.25 |
| Average Volume | 8,349 |
| 200-Day Moving Average | 28.81 |
| 50-Day Moving Average | 39.48 |
| 20-Day Moving Average | 40.21 |
| 10-Day Moving Average | 40.01 |
| Average True Range | 0.96 |
| RSI (14) | 51.22 |
| ADX | 17.15 |
| +DI | 35.11 |
| -DI | 17.42 |
| Chandelier Exit (Long, 3 ATRs) | 40.11 |
| Chandelier Exit (Short, 3 ATRs) | 41.93 |
| Upper Bollinger Bands | 40.82 |
| Lower Bollinger Band | 39.59 |
| Percent B (%b) | 0.33 |
| BandWidth | 3.07 |
| MACD Line | 0.16 |
| MACD Signal Line | 0.24 |
| MACD Histogram | -0.0777 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 44.50 | ||||
| Resistance 3 (R3) | 45.00 | 44.00 | 43.75 | ||
| Resistance 2 (R2) | 44.00 | 42.85 | 43.75 | 43.50 | |
| Resistance 1 (R1) | 42.00 | 42.15 | 43.00 | 41.50 | 43.25 |
| Pivot Point | 41.00 | 41.00 | 41.50 | 40.75 | 41.00 |
| Support 1 (S1) | 39.00 | 39.85 | 40.00 | 38.50 | 36.75 |
| Support 2 (S2) | 38.00 | 39.15 | 37.75 | 36.50 | |
| Support 3 (S3) | 36.00 | 38.00 | 36.25 | ||
| Support 4 (S4) | 35.50 |
